About Arcturus Therapeutics Holdings Inc.
https://arcturusrx.comArcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States.
CEO
Joseph E. Payne
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2017-11-16 | Reverse | 1:7 |
ETFs Holding This Stock
Summary
Showing Top 3 of 95
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
BTIG
Buy
Canaccord Genuity
Buy
Leerink Partners
Outperform
Scotiabank
Sector Outperform
Piper Sandler
Overweight
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
FEDERATED HERMES, INC.
Shares:4.69M
Value:$36.29M
BLACKROCK INC.
Shares:2.65M
Value:$20.48M
BLACKROCK, INC.
Shares:2.56M
Value:$19.82M
Summary
Showing Top 3 of 161
About Arcturus Therapeutics Holdings Inc.
https://arcturusrx.comArcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $17.15M ▼ | $30.32M ▼ | $-13.45M ▼ | -78.41% ▼ | $-0.49 ▼ | $-12.69M ▼ |
| Q2-2025 | $24.51M ▼ | $36.13M ▼ | $-9.18M ▲ | -37.45% ▲ | $-0.34 ▲ | $-10.84M ▲ |
| Q1-2025 | $29.38M ▲ | $46.21M ▼ | $-14.08M ▲ | -47.91% ▲ | $-0.52 ▲ | $-16.02M ▲ |
| Q4-2024 | $21M ▼ | $54.39M ▲ | $-30M ▼ | -142.88% ▼ | $-1.11 ▼ | $-29.19M ▼ |
| Q3-2024 | $38.81M | $49.55M | $-6.9M | -17.78% | $0.14 | $-6.21M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $180.36M ▼ | $282.34M ▼ | $57.78M ▼ | $224.56M ▼ |
| Q2-2025 | $196.47M ▼ | $309.27M ▼ | $78.22M ▼ | $231.05M ▼ |
| Q1-2025 | $216.95M ▼ | $331.79M ▼ | $98.03M ▼ | $233.76M ▼ |
| Q4-2024 | $237.03M ▼ | $344.07M ▼ | $103.09M ▼ | $240.98M ▼ |
| Q3-2024 | $237.18M | $370.65M | $108.79M | $261.87M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-13.45M ▼ | $-17.15M ▼ | $-181K ▼ | $1.23M ▲ | $-16.11M ▲ | $-17.33M ▼ |
| Q2-2025 | $-9.18M ▲ | $-5.75M ▲ | $0 ▲ | $-14.73M ▼ | $-20.48M ▼ | $-5.75M ▲ |
| Q1-2025 | $-14.08M ▲ | $-35.14M ▼ | $-137K ▼ | $15.2M ▲ | $-20.08M ▼ | $-35.27M ▼ |
| Q4-2024 | $-30M ▼ | $-284K ▲ | $0 ▲ | $134K ▼ | $-150K ▲ | $-284K ▲ |
| Q3-2024 | $-6.9M | $-23.76M | $-80K | $693K | $-23.15M | $-23.84M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Collaboration Revenue | $20.00M ▲ | $30.00M ▲ | $20.00M ▼ | $10.00M ▼ |
 Grant | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Joseph E. Payne
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2017-11-16 | Reverse | 1:7 |
ETFs Holding This Stock
Summary
Showing Top 3 of 95
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
BTIG
Buy
Canaccord Genuity
Buy
Leerink Partners
Outperform
Scotiabank
Sector Outperform
Piper Sandler
Overweight
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
FEDERATED HERMES, INC.
Shares:4.69M
Value:$36.29M
BLACKROCK INC.
Shares:2.65M
Value:$20.48M
BLACKROCK, INC.
Shares:2.56M
Value:$19.82M
Summary
Showing Top 3 of 161